These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 38623942)

  • 1. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
    Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):110-118. PubMed ID: 38623942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.
    Ma N; Bansal M; Chu J; Branch AD
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):229-237. PubMed ID: 38693784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
    Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between food insecurity and metabolic dysfunction-associated steatotic liver disease/significant fibrosis measured by fibroscan.
    Kim D; Perumpail BJ; Cholankeril G; Ahmed A
    Eur J Nutr; 2024 Apr; 63(3):995-1001. PubMed ID: 38260997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3 + and AGILE 4 scores: analysis of the NHANES 2017-2018 cycle.
    Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Polanco P; Leff P; Kumar P; Noureddin M
    BMC Gastroenterol; 2024 Jul; 24(1):218. PubMed ID: 38977950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of muscle mass, grip strength and fat-to-muscle ratio and metabolic dysfunction-associated steatotic liver disease in a middle-to-elderly aged population.
    Liu S; He Y; Yu G; Song C; Wang D; Liu L; Liang H; Wan H; Shen J
    Ann Med; 2024 Dec; 56(1):2390169. PubMed ID: 39129458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes.
    Fuhri Snethlage CM; Meijnikman AS; Mak AL; Rampanelli E; Voermans B; Callender CAK; de Groen P; Roep BO; van Raalte DH; Knop FK; Holleboom AG; Nieuwdorp M; Hanssen NMJ
    Eur J Endocrinol; 2024 May; 190(5):391-400. PubMed ID: 38679966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data from 2017 to 2020.
    Lu Y; Xu X; Wu J; Ji L; Huang H; Chen M
    BMC Gastroenterol; 2024 Sep; 24(1):300. PubMed ID: 39237899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis.
    Vega L; Simian D; Gajardo AI; Salinas M; Urra A; Cattaneo M; Pino R; Roblero JP; Urzúa Á; Rojas K; Poniachik J
    Ann Hepatol; 2024; 29(4):101511. PubMed ID: 38710474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
    Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
    Metab Syndr Relat Disord; 2024 Oct; 22(8):608-618. PubMed ID: 38868900
    [No Abstract]   [Full Text] [Related]  

  • 12. Transient Elastography Measures of Hepatic Steatosis and Fibrosis Are Associated With Body Composition Among US Adolescents.
    Unalp-Arida A; Ruhl CE
    J Pediatr Gastroenterol Nutr; 2022 Oct; 75(4):497-505. PubMed ID: 35758468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database.
    Nemer M; Osman F; Said A
    Ann Hepatol; 2024; 29(3):101491. PubMed ID: 38412922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
    Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
    BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey.
    Ciardullo S; Monti T; Perseghin G
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):384-390.e1. PubMed ID: 32623006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis.
    Vassilopoulos A; Kalligeros M; Vassilopoulos S; Shehadeh F; Benitez G; Kaczynski M; Lazaridou I; Promrat K; Wands JR; Mylonakis E
    Dig Dis Sci; 2024 Mar; 69(3):989-1003. PubMed ID: 38183561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen.
    Sharma A; Godina Leiva E; Kalavalapalli S; Lomonaco R; Marangi SA; Valdez Saenz E; Gonzalez MA; Ortiz Rocha A; Cuervo Pardo N; Rosenberg J; Bedossa P; Bril F; Barb D; Cusi K
    Obesity (Silver Spring); 2024 Oct; 32(10):1967-1974. PubMed ID: 39315409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
    Abeysekera KWM; Fernandes GS; Hammerton G; Portal AJ; Gordon FH; Heron J; Hickman M
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):295-305. PubMed ID: 31954687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.
    De Nucci S; Bonfiglio C; Donvito R; Di Chito M; Cerabino N; Rinaldi R; Sila A; Shahini E; Giannuzzi V; Pesole PL; Coletta S; Lanzilotta E; Piazzolla G; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.